Table 1 Patient demographic and baseline clinical characteristics (full analysis set).
QL1209 (N = 257) | Reference pertuzumab (N = 259) | |
|---|---|---|
Age, years; median (range) | 53 (24–71) | 53 (25–74) |
Gender, n (%) | ||
Male | 0 | 0 |
Female | 257 (100) | 259 (100) |
Race, n (%) | ||
Han | 244 (94.9) | 243 (93.8) |
Other | 13 (5.1) | 16 (6.2) |
BMI, kg/m2; median (range) | 24.22 (17.6–33.6) | 24.33 (17.0–37.5) |
Breast cancer type, n (%) | ||
Early | 161 (62.6) | 165 (63.7) |
Locally advanced | 96 (37.4) | 94 (36.3) |
Clinical TNM stage | ||
II | 134 (52.1) | 140 (54.) |
III | 111 (43.2) | 115 (44.4) |
Other | 12 (4.7) | 4 (1.5) |
Lymph node status | ||
Yes | 193 (75.1) | 193 (74.5) |
No | 64 (24.9) | 66 (25.5) |
Previous anti-tumor therapies, n (%) | 1 (0.4) | 0 |
LVEF, %; median (range) | 65 (55-81) | 66 (53-78.8) |
